Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the a...

Full description

Bibliographic Details
Main Authors: Miguel Olivas-Aguirre, Liliana Torres-López, Kathya Villatoro-Gómez, Sonia Mayra Perez-Tapia, Igor Pottosin, Oxana Dobrovinskaya
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceuticals
Subjects:
anticancer activity
anticancer treatment
adverse effects
cannabidiol
clinical trials
drug delivery
Online Access:https://www.mdpi.com/1424-8247/15/3/366

Similar Items

Similar Items